260 related articles for article (PubMed ID: 35640765)
1. Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer.
Gupta U; Saren BN; Khaparkhuntikar K; Madan J; Singh PK
J Control Release; 2022 Aug; 348():1089-1115. PubMed ID: 35640765
[TBL] [Abstract][Full Text] [Related]
2. Exciting Potential of Nanoparticlized Lipidic System for Effective Treatment of Breast Cancer and Clinical Updates: A Translational Prospective.
Harwansh RK; Bahadur S; Deshmukh R; Rahman MA
Curr Pharm Des; 2020; 26(11):1191-1205. PubMed ID: 32003686
[TBL] [Abstract][Full Text] [Related]
3. Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics.
Date T; Nimbalkar V; Kamat J; Mittal A; Mahato RI; Chitkara D
J Control Release; 2018 Feb; 271():60-73. PubMed ID: 29273320
[TBL] [Abstract][Full Text] [Related]
4. Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications.
Rajpoot K
Curr Cancer Drug Targets; 2020; 20(4):271-287. PubMed ID: 31951180
[TBL] [Abstract][Full Text] [Related]
5. Nano-drug delivery system: a promising approach against breast cancer.
Malik JA; Ansari JA; Ahmed S; Khan A; Ahemad N; Anwar S
Ther Deliv; 2023 May; 14(5):357-381. PubMed ID: 37431741
[TBL] [Abstract][Full Text] [Related]
6. Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: Role of surface engineered nanocarriers.
Gopalan D; Pandey A; Udupa N; Mutalik S
J Control Release; 2020 Mar; 319():183-200. PubMed ID: 31866505
[TBL] [Abstract][Full Text] [Related]
7. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
Ali ES; Sharker SM; Islam MT; Khan IN; Shaw S; Rahman MA; Uddin SJ; Shill MC; Rehman S; Das N; Ahmad S; Shilpi JA; Tripathi S; Mishra SK; Mubarak MS
Semin Cancer Biol; 2021 Feb; 69():52-68. PubMed ID: 32014609
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer.
Ansari MA; Thiruvengadam M; Farooqui Z; Rajakumar G; Sajid Jamal QM; Alzohairy MA; Almatroudi A; Alomary MN; Chung IM; Al-Suhaimi EA
Semin Cancer Biol; 2021 Feb; 69():109-128. PubMed ID: 31891780
[TBL] [Abstract][Full Text] [Related]
9. Lipid based nanocarriers: a translational perspective.
Mishra DK; Shandilya R; Mishra PK
Nanomedicine; 2018 Oct; 14(7):2023-2050. PubMed ID: 29944981
[TBL] [Abstract][Full Text] [Related]
10. The Application of Nanotechnological Therapeutic Platforms against Gynecological Cancers.
Keyvani V; Mollazadeh S; Riahi E; Mahmoudian RA; Tabari M; Lagzian E; Ghorbani E; Akbarzade H; Gholami AS; Gataa IS; Hassanian SM; Ferns GA; Khazaei M; Avan A; Anvari K
Curr Pharm Des; 2024; 30(13):975-987. PubMed ID: 38500284
[TBL] [Abstract][Full Text] [Related]
11. Exosome-based delivery nanoplatforms: next-generation theranostic platforms for breast cancer.
Zheng Y; Li M; Weng B; Mao H; Zhao J
Biomater Sci; 2022 Mar; 10(7):1607-1625. PubMed ID: 35188522
[TBL] [Abstract][Full Text] [Related]
12. Nanotechnology revolutionises breast cancer treatment: harnessing lipid-based nanocarriers to combat cancer cells.
Fatima Qizilbash F; Sartaj A; Qamar Z; Kumar S; Imran M; Mohammed Y; Ali J; Baboota S; Ali A
J Drug Target; 2023 Sep; 31(8):794-816. PubMed ID: 37525966
[TBL] [Abstract][Full Text] [Related]
13. Lipid-based Nanocarriers Loaded with Taxanes for the Management of Breast Cancer: Promises and Challenges.
Chaurawal N; Misra C; Raza K
Curr Drug Targets; 2022; 23(6):544-558. PubMed ID: 34431461
[TBL] [Abstract][Full Text] [Related]
14. Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics.
Garg NK; Singh B; Jain A; Nirbhavane P; Sharma R; Tyagi RK; Kushwah V; Jain S; Katare OP
Colloids Surf B Biointerfaces; 2016 Oct; 146():114-26. PubMed ID: 27268228
[TBL] [Abstract][Full Text] [Related]
15. Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites.
Cao J; Huang D; Peppas NA
Adv Drug Deliv Rev; 2020 Dec; 167():170-188. PubMed ID: 32622022
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer.
Rajana N; Mounika A; Chary PS; Bhavana V; Urati A; Khatri D; Singh SB; Mehra NK
J Control Release; 2022 Dec; 352():1024-1047. PubMed ID: 36379278
[TBL] [Abstract][Full Text] [Related]
17. New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms.
Falagan-Lotsch P; Grzincic EM; Murphy CJ
Bioconjug Chem; 2017 Jan; 28(1):135-152. PubMed ID: 27973767
[TBL] [Abstract][Full Text] [Related]
18. Folic Acid Conjugated Nanocarriers for Efficient Targetability and Promising Anticancer Efficacy for Treatment of Breast Cancer: A Review of Recent Updates.
Choudhury H; Pandey M; Wen LP; Cien LK; Xin H; Yee ANJ; Lee NJ; Gorain B; Amin MCIM; Pichika MR
Curr Pharm Des; 2020; 26(42):5365-5379. PubMed ID: 32693762
[TBL] [Abstract][Full Text] [Related]
19. Drug delivery approaches for breast cancer.
Singh SK; Singh S; Lillard JW; Singh R
Int J Nanomedicine; 2017; 12():6205-6218. PubMed ID: 28883730
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics.
Jahan S; Karim ME; Chowdhury EH
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33530291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
